K110812 is an FDA 510(k) clearance for the CT-GUIDE NEEDLE GUIDANCE SYSTEM. Classified as System, X-ray, Tomography, Computed (product code JAK), Class II - Special Controls.
Submitted by Activiews, Ltd. (Washington, US). The FDA issued a Cleared decision on June 21, 2011 after a review of 90 days - within the typical 510(k) review window.
This device falls under the Radiology FDA review panel, regulated under 21 CFR 892.1750 - the FDA radiology and imaging software oversight framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.
Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Radiology review framework, consistent with the majority of Class II 510(k) submissions.
NCT01183182
Completed
Interventional
Industry-sponsored
Safety and Effectiveness Study for a Needle Guidance System in Lung Biopsies
Confirmation of Clinical Effectiveness and Safety of CT-guided Percutaneous Lung Aspiration and Biopsy Performed With the Aid of the ActiSightTM Needle Guidance System
| Condition studied |
Lung Diseases |
| Study design |
Single group |
| Eligibility |
All sexes
· 18 Years+
|
| Principal investigator |
Paul Narinder, MD |
| Sponsor |
ActiViews Ltd.
(industry)
|
Started 2010-08-01
→
Primary completion 2011-02-01
→
Completed 2011-03-01
Primary outcome
Number of patients with successful targeting accuracy as defined by the frequency of placing the needle at a location suitable for obtaining tissue sample from the target lesion.
Secondary outcome
Total CT-Guided procedure time Patient radiation exposure during the procedure Number of CT scans during the procedure
Study completed - no results published.
This trial concluded in 2011 but has not posted
results to ClinicalTrials.gov. Completed studies without public results are common
in industry-sponsored device trials; the data may be referenced in the
510(k) Summary PDF or remain unpublished.
View full study on ClinicalTrials.gov